A new method to induce multi-drug resistance to carboplatin in a mouse model of human tongue squamous cell carcinoma

International Journal of Oral and Maxillofacial Surgery

Volumn 37, Issue 12, 2008, Pages 1141-1147

  Feng, G ^a   Wang, D Z ^b   Chen, H Q ^c   Hu, J ^b   He, J ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

carboplatin; human tongue squamous cell carcinoma; multi drug resistance; Tca8113 cell line

Indexed keywords

CARBOPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR CELL; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; COLORING AGENTS; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TETRAZOLIUM SALTS; THIAZOLES; TONGUE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 59349097215     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2008.06.014     Document Type: Article

References (22)

1. Alonso A., Almendral M.J., Curto Y., Criado J.J., Rodriguez E., and Manzano J.L. Determination of the DNA-binding characteristics of ethidium bromide, proflavine, and cisplatin by flow injection analysis: usefulness in studies on antitumor drugs. Anal Biochem 355 (2006) 157-164
2. Bruheim S., Bruland O.S., Breistol K., Maelandsmo G.M., and Fodstad O. Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res 10 (2004) 133-141
3. Chang C.C., Liang Y.C., Klutz A., Hsu C.I., Lin C.F., Mold D.E., Chou T.C., Lee Y.C., and Huang R.C. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol 58 (2006) 640-653
4. Cvijic M.E., Yang W.L., and Chin K.V. Cisplatin resistance in cyclic AMP-dependent protein kinase mutants. Pharmacol Ther 78 (1998) 115-128
5. Engel J.-B., Schally A.-V., Halmos G., Baker B., Nagy A., and Keller G. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 104 (2005) 1312-1321
6. Engel J.B., Schally A.V., Halmos G., Baker B., Nagy A., and Keller G. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins. Eur J Cancer 41 (2005) 1824-1830
7. Koshiyama M., Fujii H., Kinezaki M., Morita Y., Nanno H., and Yoshida M. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res. 21 (2001) 2925-2932
8. Kubota T., Sasano N., Abe O., Nakao I., Kawamura E., Saito T., Endo M., Kimura K., Demura H., and Sasano H. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res. 1 (1995) 1537-1543
9. Kunishio K., Okada M., Matsumoto Y., and Nagao S. Preliminary individual adjuvant chemotherapy for primary central nervous system lymphomas based on the expression of drug-resistance genes. Brain Tumor Pathol 21 (2004) 57-61
10. Loehrer P.J., and Einhorn L.H. Drugs five years later. Cisplatin. Ann Intern Med 100 (1984) 704-713
11. Matsuhashi N., Saio M., Matsuo A., Sugiyama Y., and Saji S. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time and p53 expression-dependency of anti-cancer drugs. Oncol Rep 14 (2005) 609-615
12. Miracco C., Maellaro E., Pacenti L., Del Bello B., Valentini M.A., Rubegni P., Pirtoli L., Volpi C., Santopietro R., and Tosi P. Evaluation of MDR1, LRP, MRP, and topoisomerase IIalpha gene mRNA transcripts before and after interferon-alpha, and correlation with the mRNA expression level of the telomerase subunits hTERT and TEP1 in five unselected human melanoma cell lines. Inter J Oncology 23 (2003) 213-220
13. Moureau-Zabotto L., Ricci S., Lefranc J.P., Coulet F., Genestie C., Antoine M., Uzan S., Lotz J.P., Touboul E., and Lacave R. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94 (2006) 473-480
14. Münster P., Marchion D., Bicaku E., Schmitt M., Lee J.H., DeConti R., Simon G., Fishman M., Minton S., Garrett C., Chiappori A., Lush R., Sullivan D., and Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol 25 (2007) 1955-1956
15. Pfutzner W., and Vogel J.C. Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo. Cells Tissues Organs 177 (2004) 151-159
16. 1 to control multidrug resistance (MDR). Curr Drug Targets 7 (2006) 893-909
17. Wakamatsu T., Nakahashi Y., Hachimine D., Seki T., and Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol 31 (2007) 1465-1472
18. Wang B., Ngoi S., Wang J., Chong S.S., and Lee C.G. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol Pharmacol 70 (2006) 267-276
19. Weerasinghe P., Hallock S., Tang S.C., Trump B., and Liepins A. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells. Exp Toxicol Pathol 58 (2006) 21-30
20. Welters M.J., Fichtinger Schepman A.M., Baan R.A., Jacobs Bergmans A.J., Kegel A., vander Vijgh W.J., and Braakhuis B.J. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content. DNA adduct levels and drug sensitivity in vitro and in vivo. Br J Cancer 79 (1999) 82-88
21. Wesolowska O., Wisniewski J., Duarte N., Ferreira M.J., and Michalak K. Inhibition of MRP1 transport activity by phenolic and terpenic compounds isolated from Euphorbia species. Anticancer Res 27 (2007) 4127-4133
22. Yoshida K., Tanabe K., Ueno H., Ohta K., Hihara J., Toge T., and Nishiyama M. Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 1 (2003) 82-89